Sweden · Delayed Price · Currency is SEK ExpreS2ion Biotech Holding AB Earnings Call Transcripts
Fiscal Year 2025
-
Q4 and full year 2025 saw strong clinical and financial progress, with income up 56% year-on-year and a significantly improved underlying net loss. The pipeline advanced in oncology and infectious diseases, supported by grant funding and a solid cash position for 2026 milestones.
-
A novel HER2-targeted therapeutic vaccine is advancing through phase I trials, showing promising immune responses and potential to address high unmet needs in breast cancer. The therapy targets a large, growing market and is supported by a strong pipeline, recent partnerships, and a solid financial position.
-
Q3 saw strong execution with increased income, improved net loss, and expanded global partnerships, including a major malaria vaccine license. Cash runway extends into Q2 2026, with key clinical and partnership milestones expected over the next 18 months.
-
A novel immunotherapy targeting all HER2 domains in breast cancer shows strong preclinical and early clinical results, with phase I data progressing and broader market expansion planned. Strategic partnerships and prudent financial management support a EUR 5 billion+ addressable market.
-
Strong pipeline progress with the breast cancer vaccine trial expanding and new partnerships in malaria and influenza. H1 2025 income rose 61% year-over-year, with a SEK 49 million cash position providing runway through Q1 2026. Key data readouts expected in 2026.
-
Q1 saw a 90% rise in operating income and 44% growth in net sales, with a reduced net loss and strong cash position. ESGBC001 phase I trial is advancing with protocol amendments, while infectious disease programs progress through grant funding and partnerships.
Fiscal Year 2024
-
Q4 2024 saw a 5% drop in operating income and a SEK 16 million net loss, but year-end cash rose to SEK 82 million. Key milestones included CTA approval for the breast cancer vaccine, a major warrant subscription, and ongoing negotiations with the Serum Institute for malaria vaccines.
-
Q3 saw a narrowed net loss and reduced costs, with SEK 76 million in cash and a successful rights issue. Key milestones include a pending phase 1 trial for the breast cancer vaccine, a term sheet with Serum Institute of India, and progress in grant-funded projects.
-
H1 2024 saw improved financials with a net profit in Q2, boosted by a SEK 22.5 million dividend and a SEK 30 million rights issue. The lead breast cancer vaccine candidate is on track for a phase I trial in Q1 2025, with funding dependent on warrant exercises.